Entera Bio Statistics
Total Valuation
Entera Bio has a market cap or net worth of $466.11 million. The enterprise value is $455.23 million.
| Market Cap | 466.11M |
| Enterprise Value | 455.23M |
Important Dates
The next estimated earnings date is Friday, November 13, 2026, after market close.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Entera Bio has 173.92 million shares outstanding. The number of shares has increased by 15.33% in one year.
| Current Share Class | 173.92M |
| Shares Outstanding | 173.92M |
| Shares Change (YoY) | +15.33% |
| Shares Change (QoQ) | +5.64% |
| Owned by Insiders (%) | 0.88% |
| Owned by Institutions (%) | 13.25% |
| Float | 127.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 18.18 |
| P/TBV Ratio | 64.15 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.98, with a Debt / Equity ratio of 0.06.
| Current Ratio | 8.98 |
| Quick Ratio | 5.42 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.30 |
Financial Efficiency
Return on equity (ROE) is -138.92% and return on invested capital (ROIC) is -71.57%.
| Return on Equity (ROE) | -138.92% |
| Return on Assets (ROA) | -45.98% |
| Return on Invested Capital (ROIC) | -71.57% |
| Return on Capital Employed (ROCE) | -82.87% |
| Weighted Average Cost of Capital (WACC) | 12.44% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$774,227 |
| Employee Count | 22 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +12.61% in the last 52 weeks. The beta is 1.41, so Entera Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.41 |
| 52-Week Price Change | +12.61% |
| 50-Day Moving Average | 2.88 |
| 200-Day Moving Average | 1.84 |
| Relative Strength Index (RSI) | 48.04 |
| Average Volume (20 Days) | 648,197 |
Short Selling Information
The latest short interest is 2.40 million, so 1.38% of the outstanding shares have been sold short.
| Short Interest | 2.40M |
| Short Previous Month | 1.28M |
| Short % of Shares Out | 1.38% |
| Short % of Float | 1.89% |
| Short Ratio (days to cover) | 5.80 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -14.40M |
| Pretax Income | -17.03M |
| Net Income | -17.03M |
| EBITDA | -14.37M |
| EBIT | -14.40M |
| Earnings Per Share (EPS) | -$0.35 |
Balance Sheet
The company has $11.31 million in cash and $425,000 in debt, with a net cash position of $10.88 million or $0.06 per share.
| Cash & Cash Equivalents | 11.31M |
| Total Debt | 425,000 |
| Net Cash | 10.88M |
| Net Cash Per Share | $0.06 |
| Equity (Book Value) | 7.27M |
| Book Value Per Share | 0.15 |
| Working Capital | 16.79M |
Cash Flow
In the last 12 months, operating cash flow was -$10.89 million and capital expenditures -$73,000, giving a free cash flow of -$10.96 million.
| Operating Cash Flow | -10.89M |
| Capital Expenditures | -73,000 |
| Depreciation & Amortization | 31,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -10.96M |
| FCF Per Share | -$0.06 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Entera Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -15.33% |
| Shareholder Yield | -15.33% |
| Earnings Yield | -3.65% |
| FCF Yield | -2.35% |
Analyst Forecast
The average price target for Entera Bio is $9.75, which is 263.81% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.75 |
| Price Target Difference | 263.81% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Entera Bio has an Altman Z-Score of -7.26 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.26 |
| Piotroski F-Score | 1 |